Navigation Links
Synthetic Biologics Completes $10.8 Million Private Placement Financing
Date:10/31/2012

ROCKVILLE, Md., Oct. 31, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, announced today the successful completion of its previously announced private placement in connection with stock purchase agreements dated October 25, 2012. The Company sold approximately 6.8 million shares of its common stock at a purchase price of $1.60 per share to new and existing investors for gross proceeds of approximately $10.8 million. This transaction was completed at a discount to market and no warrants were issued to the investors. Existing investors and an affiliate of R.J. Kirk constituted a majority of the participating investors in this transaction.

"We are very pleased to complete this financing and to receive such solid support from both our new and existing investors, who share our vision of the emerging field of synthetic biologics," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics, Inc. "This new capital provides us with a strong cash position going forward. It allows us to advance our lead programs to develop monoclonal antibody therapies for certain infectious diseases and a synthetic DNA-based therapy for pulmonary arterial hypertension through our Exclusive Channel Collaborations with Intrexon Corporation. We believe that we are well-positioned to achieve significant milestones related to these cutting edge development programs."

In addition to funding the Company's monoclonal antibody and synthetic DNA programs, the net proceeds are intended to be used for general corporate purposes, including the execution of its business plan as well as the expansion and advancement of its pipeline.

The common stock sold in the private placement transaction has not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws and was issued and sold in
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synthetic Biologics Announces $10.8 Million Financing
2. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
3. Synthetic Biology Market is Expected to Reach USD 16.7 Billion Globally in 2018: Transparency Market Research
4. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
5. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
6. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
7. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
8. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
9. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
10. Adeona Becomes Synthetic Biologics, Inc.
11. Startling results in synthetic chemistry presented in Nature Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 2014 Continental Clinical Solutions, LLC ... clinical trials at its mid-Atlantic late-phase research facility, ... created with the idea of closing patient disparities ... in medical advances," said Continental's CEO, Saleh ... the immortal cell line of Henrietta Lacks, dubious ...
(Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated ... company committed to the fostering and monetization of ... v. VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  ... No. 3:13-cv-03496-M, both in the United States District ... Texas . On November ...
(Date:11/22/2014)... Two new educational webinars hosted by DrugDev ... research and how the pharmaceutical industry can make life easier ... Where Does the ALS Money Go? , Featuring guest speaker ... 1:30pm ET, Register to attend , This webinar ... Julianne Dorn Professor of Neurology at Massachusetts General Hospital at ...
(Date:11/22/2014)... November 21, 2014 CannLabs, Inc. ... based analytics and scientific testing methodologies relating to cannabis, ... a $750,000 line of credit from an existing stockholder ... to have secured this commitment from one of our ... of CannLabs. “This capital will help accelerate our planned ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Markman Hearing Held as Scheduled in VTech and Uniden Cases 2DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2CannLabs Secures $750,000 Line Of Credit 2
... National Institutes of Health. Madison, Wis. ... on Wednesday that it will receive a $1.26 million Phase ... of Health. , ,The funds will be used to help ... blood disorder that kills red blood cells. This results in ...
... conference at Grainger Hall. Madison, Wis. ... Wisconsin, according to the Coalition for Capital Growth and Research, ... Hall. , ,We believe [venture capital] is a worthwhile agenda ... partner at Venture Investors and the conferences founder. ...
... Teresa Esser Pel-Freez Clinical Systems, LLC began as ... flourished during the World Wars because unlike other meats, ... Pel-Freez Rabbit Meat, Inc. relocated to Rogers, Arkansas, because ... , ,During the 1960s, the companys managers realized that ...
Cached Biology Technology:Mirus receives $1.26 million SBIR grant to combat anemia 2Wisconsin investors seek regional partners and informed legislature 2Wisconsin investors seek regional partners and informed legislature 3An entrepreneurial success story Frank Langley champions biocapitalism 2An entrepreneurial success story Frank Langley champions biocapitalism 3An entrepreneurial success story Frank Langley champions biocapitalism 4An entrepreneurial success story Frank Langley champions biocapitalism 5
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
(Date:11/10/2014)... on U.S. store shelves in early 2010, and people ... small packets can be tossed into a washing machine ... powder. The convenience, though, has come with risks for ... Nationwide Children,s Hospital found that from 2012 through 2013, ... younger than 6 years of age swallowing, inhaling, or ...
(Date:11/6/2014)... deaths occur because of metastasis, yet progress in ... slow. , "It,s been particularly challenging to design ... research fellow in systems biology at Harvard Medical ... until after they,ve already metastasized." , Gujral and ... should help researchers better understand how metastasis begins. ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3
... detailed analysis to date of how humans differ from one ... selection has shaped the recent evolution of our species, according ... , In a study published in the Oct. 20 ... comparing how genes vary not only among 39 humans but ...
... found only in hops and the main product they are ... a micronutrient that might help prevent many types of cancer. ... properties of this flavonoid compound called xanthohumol about 10 years ... journal Phytochemistry outlines the range of findings made since then. ...
... A human DNA-associated protein called LEDGF is the first ... integration in human cells, according to a new study ... Medicine. , This study, published in this week's early ... target for modulating where viruses insert into the human ...
Cached Biology News:Cornell finds natural selection in humans 2Cornell finds natural selection in humans 3Anti-cancer Compound In Beer Gaining Interest 2Anti-cancer Compound In Beer Gaining Interest 3HIV inserts into human genome using a DNA-associated protein 2
MOUSE ANTI HUMAN FACTOR I...
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed. Free windows version for academic use....
GFX PCR DNA,Gel Band Purif,100, 1 EA. Category: Nucleotide Sample Handling....
Full service including gene cloning, protien expression and purification of 1 liter culture....
Biology Products: